Israeli drug company Can-Fite BioPharma has completed preclinical trials testing the metabolism and excretion of its lead drug CF101 for the treatment of rheumatoid arthritis (RA). The trials are being conducted as part of the preliminary process for Phase IIb trials.
The latest trials found that CF101 does not break down in the liver and is excreted in its entirety in urine discharges, thereby reducing the development of side effects. The drug could be effective in treating liver-related conditions such as cirrhosis, liver cancer and hepatitis B and C.
The trial results support the company's development program for CF101's promotion as a treatment for rheumatoid arthritis under the framework of Phase II trials, noted Pnina Fishman, CEO of Can-Fite.